Business
BIOQUAL Presents Financial Results for Fiscal Year 2019 and Declares Dividend
BIOQUAL Presents Financial Results for Fiscal Year 2019 and Declares Dividend.
About this update from Bioqual, Inc.
[{"type":"text","content":"\nBIOQUAL, Inc. (OTC Pink: BIOQ) ( www.bioqual.com):\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\n\n2019\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n2018\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\nRevenue \n\n\n\n\n\n\n$\n\n\n\n39,478,079\n\n\n\n\n\n$\n\n\n\n35,884,965\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\nIncome Before Income Tax\n\n\n\n\n\n\n$\n\n\n\n3,709,246\n\n\n\n\n\n$\n\n\n\n5,286,278\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\nNet Income\n\n\n\n\n\n\n$\n\n\n\n2,830,875\n\n\n\n\n\n$\n\n\n\n3,662,070\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\nBasic Earnings per Share\n\n\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\nof Common Stock\n\n\n\n\n\n\n$\n\n\n\n3.17\n\n\n\n\n\n$\n\n\n\n4.10\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\nDiluted Earnings per Share\n\n\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\nof Common Stock\n\n\n\n\n\n\n$\n\n\n\n3.17\n\n\n\n\n\n$\n\n\n\n4.10\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\nWeighted Average\n\n\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\nNumber of Shares Outstanding\n\n\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n\n\n\nFor Basic Per Share\n\n\n\n\n\n\n \n\n\n\n893,416\n\n\n\n\n\n \n\n\n\n893,416\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\nWeighted Average\n\n\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\nNumber of Shares Outstanding\n\n\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n\n\n\nFor Diluted Earnings Per Share\n\n\n\n\n\n\n \n\n\n\n893,655\n\n\n\n\n\n \n\n\n\n893,448\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\nBIOQUAL’s Board of Directors has declared a dividend of $.70 per share for shareholders of record on September 25, 2019, payable on October 16, 2019. This is the eighteenth dividend declared by BIOQUAL.\n\n\nStatements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in a...